DELSIA, an independent not-for-profit affiliate of Autism Speaks, will focus on accelerating the translation of scientific breakthroughs into products that will improve quality of life and health for those affected by autism.
Clara Lajonchere, Ph.D., Autism Speaks vice president for clinical programs, will be a featured speaker at the biannual conference of the Autism Research Institute (ARI), October 13-14, in Anaheim, Calif.
Many ACE Grants Based on Autism Speaks 'Seed' Money
Unexpected Gene Functions Shown in Initial Studies
High-Priority Research Will Study the Impact of the Proposed DSM-5 on Autism Diagnosis and much more!
The deal will pool the resources of Roche, the Swiss pharmaceutical giant, and Seaside Therapeutics, a private 30-employee company based in Cambridge, Mass.
A new study from the UC Davis M.I.N.D. Institute found that women who ran a fever during pregnancy had twice the risk of having a baby with autism. The study offered an easy fix, too: Women who controlled the fever with Tylenol or a similar fever-reducing medication eliminated the risk. PMID 22562209.
Brings Together More Than 1800 Participants From Around the World to Discuss the Latest Findings on the Causes, Treatments and Diagnoses of Autism
Autism Speaks announced a partnership with its Autism Genetic Resource Exchange (AGRE) program and Prometheus Research to build a data management system that will support the integration and centralization of several of Autism Speaks leading data and biospecimen repositories.
In November 2011, scientists from around the world gathered in Arlington, Virginia, to discuss how the emerging picture of autism brain pathways can lead to effective treatments for those struggling with disabling symptoms.
Pharmaceutical Companies, Advocacy Organizations, and Universities Join Forces to Discover New Drugs and Assess Novel Treatment Approaches for Autism
This webinar is geared towards researchers performing copy number and allelic event analysis of the Autism Spectrum Disorders. It is also applicable to anyone interested in a more efficient system to extract meaningful results from genomic aberration data.